Filmmaker's Hansal Mehta's Mounjaro journey: Is it safe for prediabetes?
Is Mounjaro good for prediabetes?
Mounjaro, the brand name for tirzepatide, mimics the function of natural hormones GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1). It has a double effect, of increasing insulin secretion in response to food intake and improving glucose control and weight loss. It is officially approved for Type 2 diabetes and weight loss in people with obesity or overweight plus related health conditions.
Using it for prediabetes is off-label — which can still be appropriate — but should always involve careful clinical oversight. Research suggests it may also help prevent the progression of prediabetes to type 2 diabetes, especially in individuals with obesity or who are overweight. Remember its use depends on how severe your condition is,
your age, other drugs you're taking to lower blood sugar levels and other conditions you may have. Also it's not a substitute for lifestyle changes like diet and exercise.
Is Mounjaro sustainable long-term?
GLP-1/GIP medications can result in weight regain if stopped without a solid maintenance plan. Lifestyle must remain the foundation of metabolic health. Many patients forget that both have to be in tandem and do not link weight loss with weight maintenance. While the drug does half the work, the other work depends on individual agency.
To that extent, the filmmaker did take positive steps. For example, a high-protein diet stabilizes blood sugar and preserves lean muscle.Strength training is not a difficult deal either. A simple strength training routine for weight loss involves squats, lunges, push-ups with light cardio like walking or cycling. This can be done every alternate day of the week. Equal importance has to be given to hydration and sleep hygiene. Water facilitates the kidneys' ability to filter excess glucose and dilute blood sugar. Poor sleep can increase insulin resistance, leading to higher blood sugar levels. Deep sleep enhances insulin sensitivity and improves glucose absorption
Is intermittent fasting a good option?
Though intermittent fasting is popular, I believe the primary target should be to restrict calories daily.
Exercise caution on supplements
NMN and Resveratrol supplements, as mentioned by the filmmaker, are promising in the longevity field, but still lack large-scale human data. Anyone considering them should consult a healthcare provider, especially if on other medications.
The emphasis on destigmatising the use of metabolic medication is important. Weight gain, insulin resistance and prediabetes aren't just lifestyle issues — they're also deeply tied to genetics and biology. Using the right tools with medical guidance is nothing to be ashamed of.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
6 hours ago
- Time of India
Danone targets consumers taking weight loss drugs with new drink
Danone is introducing an Oikos brand drink targeting U.S. consumers using weight loss medications such as Wegovy , pledging the dairy-based beverage helps address the common concern of retaining muscle. Patients on GLP-1 medications like Zepbound often shed valuable muscle rather than fat, worrying doctors and requiring diet changes, such as eating more protein. Danone's new drink, called Oikos Fusion, has nutrients such as vitamin D and whey protein that the French company says help build and maintain muscle. Danone is the latest food maker seizing the opportunity to sell new products to consumers dropping weight with GLP-1s, which users usually inject and are sometimes called "the shot." The market is set to grow as drug makers look to develop the appetite-suppressing medication in pill form. U.S. packaged food maker Conagra started labeling its Healthy Choice frozen meals "GLP-1" friendly, while rival Nestle launched Vital Pursuit to serve those on the medicine. The frozen pizzas and pasta bowls generally offer higher amounts of protein and come in smaller portions. Danone earlier this year introduced another high-protein Oikos smoothie to compete with Coca-Cola's wildly popular Fairlife. PepsiCo is also getting into "liquid protein" as Americans add more to their diet. Danone's sales in North America grew more than 2% in its second quarter, in part because of Oikos, which is mostly a yogurt brand. "This is a brand that has been growing at a rapid pace in the marketplace and strategically expanding," said Rafael Acevedo, president of yogurt at Danone North America. Single bottles of the new drink will first be sold in Walmart for $2.12.
Time of India
7 hours ago
- Time of India
When people slim down, businesses bulk up
Mumbai: The growing popularity of weight-loss drugs Mounjaro and Wegovy may open new growth avenues for non-pharma businesses like textiles, apparel, fitness chains, and food and beverages, besides boosting wellness services such as dental care, aesthetics, dermatology, cosmetology, and plastic surgery . Around 100,000 people in the country are estimated to be using these drugs and the figure is expected to surge to 1.2 million within two years, driving demand across the industries. Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program "Made-to-measure and custom tailoring is a trend that will intensify," said Neeraj Nagpal, chief business officer, apparel and retail, at Raymond Lifestyle . by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Undo The apparel maker is weaving health-consciousness into its design strategy - to address a possible rise in demand for "a sharper look" post weight loss. "We have the ingredients, infrastructure, process, knowhow and we have the experience and legacy of delivering at scale to ride on where the wind blows," Nagpal said. Live Events Places like the US where GLP-1 (glucagon-like peptide-1) weight-loss drugs have become a rage, apparel brands are noticing a shift in people's shopping habits. Globally, clothing companies like athletic apparel retailer Lululemon are seeing sizes like S and M flying off the shelves more quickly than usual, according to a report by Investec. "People on GLP drugs are now demanding smaller sizes as their body sizes reduce and this has made companies monitor their sell-through rates to see which sizes are performing better than others," the report stated. Data indicates that customers on GLP-1 drugs are likely to buy more apparel within their first year of being on the medication, it said. The number of Indians using weight-loss drugs is projected to reach four million by 2029-30, aided by an expected drop of up to 80% in the price of semaglutide (Wegovy) after its patent expires in March 2026, paving the way for multiple Indian generics. Several industries are expected to get a tailwind from this. Fitness centres may see a rise in sign-ups as consumers of weight-loss drugs are required to engage in muscle and strength training, said doctors and industry experts. Dermatologists are hoping to receive a lot of patient call with concerns around hair loss, skin sagging, stretch marks and dry skin; dental and aesthetic surgeons are expecting a rise in cases of teeth enamel erosion among people who use weight-loss drugs; orthopaedics foresee muscle loss due to the weight drugs, triggering several cases of back ache and knee pain. "Dermatology will get more tailwind because when people lose weight, it will affect the skin tone and texture, especially if it is unsupervised without proper nutrition and lifestyle change," said Neeraj Tulara, general medicines and infectious diseases specialist at LH Hiranandani Hospital at Powai, Mumbai. The weight-loss medications will also lead to significant muscle loss along with fat loss. That is why these medications are advised with strength training. "If there is a 25-30% weight loss, it will significantly affect the shape of the body," Tulara said. "And once there is muscle loss, the business of dermatologists, cosmetologists and plastic surgeons will increase as more people on weight-loss drugs will approach them to address issues like change in skin tone and texture, skin sagging, etc." Dental would be more of an indirect impact like loss of enamel and gums-related issues due to muscle loss, doctors said. However, any deficiency will happen only when one is not eating properly - because along with weight loss, there is need for dietary consultation and strength training to build muscles, they said. The full impact of the drugs, though, is yet to unfold as it is still early days, they added. "If the weight loss has been unsupervised or very rapid, people come to us for hair loss," said Maithili Kamat, consultant dermatologist and trichologist at Jaslok Hospital. Any calorie deficit due to suppression of appetite and if it is unsupervised without proper nutrients or a high protein diet, there will be hair loss, which also happens after bariatric surgery, she said. Food companies may also see a mark-up in sales of healthy snacks and protein-rich diets. According to a report by consulting major PwC, weight-loss drugs change the way people think about their food and beverage intake.
Indian Express
16 hours ago
- Indian Express
Can blockbuster weight loss drugs affect your eyes? Here's what new studies have found
Can the new class of diabetes and obesity medicines, which are being hailed as blockbuster weight loss drugs, affect your eyesight? Two recent studies, published in JAMA Network Open, have now confirmed the association of semaglutide and tirzepatide with an increased risk of certain eye conditions. Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue, which mimics the effects of the natural GLP-1 hormone in the body, regulating blood sugar levels and appetite. It is used to treat type 2 diabetes and, in higher doses, for weight management. Tirzepatide mimics the effect of both GLP1 and GIP, a hormone that stimulates insulin release from the pancreas and helps regulate blood sugar and weight. Researchers focussed on how these drugs were linked to diabetic retinopathy (a condition where high blood sugar levels damage the tiny blood vessels in the retina and can cause blindness) and NAION (Non-arteritic Anterior Ischemic Optic Neuropathy, a condition where blood flow to the nerve reduces, leading to sudden, painless vision loss). The first study looked at data of people with Type 2 diabetes on any GLP-1 medicine (including older molecules such as dulaglutide and liraglutide) and compared it with people on other diabetes medications. During the two-year follow-up, the researchers found that the risk of both diabetic retinopathy and NAION was higher in those taking GLP-1 medicines. The good news, however, was that these medicines were linked to a lower all-cause blindness and lower rate of the sight-threatening complications of diabetic retinopathy such as bleeding in the space between the lens and retina of the eye or a severe form of eye condition where blood vessels grow abnormally in the eye. In patients with diabetic retinopathy, the use of the medicine did not lead to progression to advanced stages. The researchers also noted a reduced need for medical, surgical, or laser-based treatments for these conditions. The second study compared the patients who were on the strongest GLP-1 medicines like semaglutide and tirzepatide with those on any other diabetes medicines including insulin, metformin, or even the older GLP-1 medicines. During the two-year follow-up period, the researchers noted a slight increase in cases of NAION and other optic nerve disorders. The studies were conducted to verify concerns about diabetic retinopathy that were raised nearly a decade ago during the initial trials of semaglutide. This prompted heightened scrutiny for eye diseases and led to the exclusion of high-risk individuals from further trials. More recently, a study from a single centre showed an increase in incidence of NAION in patients on semaglutide. This prompted further studies to understand the impact of these medicines on the eye. The European Medicines Agency now says that NAION is an extremely rare adverse reaction that may affect one in 10,000 people who are on semaglutide. Similar studies would now be needed for tirzepatide as well. Should you continue taking your prescription? Yes. The researchers say while there is some increased risk of these eye conditions, the GLP-1 medicines themselves have been transformative when it comes to diabetes and obesity management. There is also evidence coming in to show the benefit of these medicines on heart, kidney, and liver conditions linked to diabetes and obesity. Researchers say patients should be informed about the risk of eye conditions when they are prescribed the drugs. They suggest that people who already have diabetic retinopathy should undergo close ophthalmic monitoring when the drugs are initiated or when the doses are increased. They recommend that the medicines be gradually upgraded to avoid sudden swings in blood glucose levels that can affect the eye. For this purpose, they suggest a collaboration between diabetologists and eye specialists. The researchers have further suggested that parameters for eye safety be made a part of all future GLP-1 medicine trials.
